Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Durez

Showing results (61-70 of 118) with videos related to

Pageof 12
Sort By:
Annals of the Rheumatic Diseases|October 28, 2021
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated databasePeter C Taylor, Tsutomu Takeuchi, Gerd R Burmester, et al.
Annals of the Rheumatic Diseases|March 20, 2014
Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb studyMark C Genovese, Roy Fleischmann, Daniel Furst, et al.
Arthritis and Rheumatism|April 3, 2008
Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging studyJonathan Kay, Eric L Matteson, Bhaskar Dasgupta, et al.
Rheumatology and Therapy|May 18, 2023
Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension StudyAlan Kivitz, Alvin F Wells, Juan I Vargas, et al.
Journal of Translational Medicine|January 8, 2020
Glycosylation deficiency of lipopolysaccharide-binding protein and corticosteroid-binding globulin associated with activity and response to treatment for rheumatoid arthritisFederica Ciregia, Dominique Baiwir, Gaël Cobraiville, et al.
The Journal of Rheumatology|April 4, 2006
A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritisRené Westhovens, Frédéric Houssiau, Johan Joly, et al.
Rheumatology (Oxford, England)|December 13, 2021
Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 programCharles G Peterfy, Vibeke Strand, Alan Friedman, et al.
Expert Review of Clinical Immunology|December 11, 2020
Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysisRoberto Caporali, Yannick Allanore, Rieke Alten, et al.
Frontiers in Immunology|December 17, 2020
Paired Rheumatoid Arthritis Synovial Biopsies From Small and Large Joints Show Similar Global Transcriptomic Patterns With Enrichment of Private Specificity <i>TCRB</i> and TCR Signaling PathwaysClement Triaille, Louise Vansteenkiste, Manuel Constant, et al.
Rheumatology International|October 2, 2014
Further international adaptation and validation of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaireJeanette Wilburn, Stephen P McKenna, James Twiss, et al.
Pageof 12

Showing results (61-70 of 118) with videos related to

Sort By:
Pageof 12
Annals of the Rheumatic Diseases|October 28, 2021
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated databasePeter C Taylor, Tsutomu Takeuchi, Gerd R Burmester, et al.
Annals of the Rheumatic Diseases|March 20, 2014
Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb studyMark C Genovese, Roy Fleischmann, Daniel Furst, et al.
Arthritis and Rheumatism|April 3, 2008
Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging studyJonathan Kay, Eric L Matteson, Bhaskar Dasgupta, et al.
Rheumatology and Therapy|May 18, 2023
Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension StudyAlan Kivitz, Alvin F Wells, Juan I Vargas, et al.
Journal of Translational Medicine|January 8, 2020
Glycosylation deficiency of lipopolysaccharide-binding protein and corticosteroid-binding globulin associated with activity and response to treatment for rheumatoid arthritisFederica Ciregia, Dominique Baiwir, Gaël Cobraiville, et al.
The Journal of Rheumatology|April 4, 2006
A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritisRené Westhovens, Frédéric Houssiau, Johan Joly, et al.
Rheumatology (Oxford, England)|December 13, 2021
Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 programCharles G Peterfy, Vibeke Strand, Alan Friedman, et al.
Expert Review of Clinical Immunology|December 11, 2020
Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysisRoberto Caporali, Yannick Allanore, Rieke Alten, et al.
Frontiers in Immunology|December 17, 2020
Paired Rheumatoid Arthritis Synovial Biopsies From Small and Large Joints Show Similar Global Transcriptomic Patterns With Enrichment of Private Specificity <i>TCRB</i> and TCR Signaling PathwaysClement Triaille, Louise Vansteenkiste, Manuel Constant, et al.
Rheumatology International|October 2, 2014
Further international adaptation and validation of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaireJeanette Wilburn, Stephen P McKenna, James Twiss, et al.
Pageof 12